BCL2 and cancer: In recent years, several BCL-2 protein inhibitors have been developed (Oblimersen, ABT-737, ABT-263, obatoclax mesylate, AT-101, and S55746), to specifically target BCL-2 protein for cancer treatments [15,16,17].